CD4 and neoplasm: These data suggest that Mito‐ATO drives an adaptive T cell tumor‐specific immune response including an increase in cytotoxic CD4+ T cells that results in lung tumor regression; the decline in immunosuppressive G‐MDSCs and Tregs in the tumors of Mito‐ATO‐treated mice may have allowed for the expansion of CD4+ T cells.